NASDAQ · FSTX
F-star Therapeutics, Inc.
$7.12$0.00 (0.0%)
F-star Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
NASDAQ · SELB · USD
Stock price, earnings
Quote as of Nov 13, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Selecta Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Selecta Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of innovative nanoparticle immunomodulatory medications aimed at treating and preventing various human ailments. The company's most advanced gene therapy initiative is SEL-302, currently in preclinical development to enhance therapeutic options for methylmalonic acidemia. Among its biologic therapies, SEL-212 is undergoing Phase III clinical trials for the management of chronic refractory gout. Selecta is also advancing potential treatments for a range of IgA-mediated conditions, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. Their gene therapy pipeline further includes SEL-313, a preclinical candidate targeting ornithine transcarbamylase deficiency, and SEL-399, which is designed to ascertain the optimal ImmTOR dosage for minimizing the formation of antibodies to AAV capsids. Additionally, they are developing gene therapies for conditions such as Pompe disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorders, and other autoimmune diseases. The company is also exploring tolerogenic therapies for primary biliary cholangitis and other autoimmune disorders. Selecta Biosciences, Inc. has established licensing and collaboration agreements with a diverse group of partners, including Takeda Pharmaceuticals USA, Inc., Swedish Orphan Biovitrum, Sarepta Therapeutics, Inc., Asklepios Biopharmaceutical, Inc., Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., Ginkgo Bioworks Holdings, Inc., and IGAN Biosciences, Inc. Founded in 2007, Selecta Biosciences, Inc. is headquartered in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $16.80M+43.79% vs estimate |
| Q3 2022 | Nov 3, 2022 | -$0.01-777.19% vs estimate | $20.71M |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.12$0.00 (0.0%)
F-star Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$2.18+$0.02 (+0.93%)
Pardes Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.6% below the high.
$1.54-$0.02 (-1.28%)
NGM Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.16% below the high.
$0.63+$0.04 (+7.29%)
Sesen Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
$2.23+$0.04 (+1.83%)
Paratek Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.9% below the high.
$2.65-$0.01 (-0.38%)
Kinnate Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.12% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
